LI
LKFT

Leap Investments’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Leap Investments’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,100
Closed -$216K – 464
2020
Q1 		$216K Buy
+1,100
New +$237K 0.32% 139

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Leap Investments's LKFT Position: Q2 2020 in Review

Leap Investments sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2020, closing a stake of 1,100 shares — an estimated $216K sold.

Leap Investments first reported a position in LKFT in Q1 2020 and held it in 1 quarter. The position peaked at $216K in Q1 2020. 142 funds tracked by Wall St. Rank hold LKFT as of Q2 2020.

  • Leap Investments reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2020 after selling out during the quarter.
  • Leap Investments sold 1,100 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2020, an estimated $216K.
  • Leap Investments first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2020 and held it in 1 quarter.
  • Leap Investments's Lakefront Biotherapeutics American Depositary Shares position peaked at $216K in Q1 2020.
  • 142 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.